SOST and hypopigmentation, organomegaly, and delayed myelination and development: Thus, treatment with the anti-sclerostin antibody (Romosozumab—AMG 785, UCB, Union Chimique Belge, Brussels, Belgium) may be an interesting strategy to fight osteoporosis in patients with HOD [274,275].